Joshua Richter, MD, discusses the evolving treatment landscape in relapsed/refractory multiple myeloma.
January 20th 2023
Joshua Richter, MD, gives an overview of treatment options in multiple myeloma and factors that influence treatment decisions.
Expert oncologist Joshua Richter, MD, defines triple-class refractory multiple myeloma and describes selinexor’s unique mechanism of action.
January 27th 2023
An overview of recent data on selinexor, carfilzomib, and dexamethasone in triple-class refractory multiple myeloma, and treatment options to replace belantamab.
An expert oncologist evaluates the effect of combination trials of bispecific antibodies on the multiple myeloma treatment landscape.
February 3rd 2023
Joshua Richter, MD, offers advice to community oncologists and discusses unmet needs in the treatment of patients with relapsed/refractory MM.